David Van Duin

David Van Duin

Infectious Disease
101 Manning Dr
Chapel Hill, NC 27514

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 201 publications

Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.

Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.

Journal: Antimicrobial agents and chemotherapy
Published: May 15, 2026

Sulbactam-durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz-Hugh-Curtis syndrome.

Sulbactam-durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz-Hugh-Curtis syndrome.

Journal: Antimicrobial agents and chemotherapy
Published: April 30, 2026

Development and Application of an Anaerobic Activity Index.

Development and Application of an Anaerobic Activity Index.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 29, 2026

Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan.

Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan.

Journal: Microbiology spectrum
Published: April 27, 2026

A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.

A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.

Journal: mBio
Published: April 08, 2026

Development of a Kidney Transplant-Specific DOOR for Urinary Tract Infections Assessing the Impact of Carbapenem Resistance.

Development of a Kidney Transplant-Specific DOOR for Urinary Tract Infections Assessing the Impact of Carbapenem Resistance.

Journal: Transplant infectious disease : an official journal of the Transplantation Society
Published: December 08, 2025

Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.

Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.

Journal: BMC infectious diseases
Published: November 26, 2025

A patient-centric paradigm and tool for clinical research: the DOOR is open.

A patient-centric paradigm and tool for clinical research: the DOOR is open.

Journal: Antimicrobial agents and chemotherapy
Published: November 24, 2025

Impact of eravacycline on fibrinogen.

Impact of eravacycline on fibrinogen.

Journal: The Journal of antimicrobial chemotherapy
Published: October 30, 2025

Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset.

Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset.

Journal: Open forum infectious diseases
Published: August 19, 2025

Protein Malnutrition Facilitates Intestinal Colonization with Highly Resistant Klebsiella pneumoniae.

Protein Malnutrition Facilitates Intestinal Colonization with Highly Resistant Klebsiella pneumoniae.

Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 07, 2025
Showing 1-12 of 201

Last Updated: 09/26/2026